[144] Ionis Pharmaceuticals, Inc. SEC Filing
Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).
Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.
Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.
Tipo di deposito: Avviso Form 144 per Ionis Pharmaceuticals, Inc. (IONS).
Vendita proposta: 10,000 azioni di Common Stock tramite Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) il 08/06/2025, con un valore di mercato aggregato di $419,292.00. La segnalazione indica 159,391,229 azioni in circolazione.
Dettagli sull'acquisizione: 42,223 azioni acquisite come Restricted Stock Units il 01/15/2017; pagamento: contanti. La segnalazione riporta "Nothing to Report" per titoli venduti negli ultimi 3 mesi. I campi relativi all'identit脿 del dichiarante/CIK e al contatto per l'invio non sono forniti nel contenuto del modulo.
Tipo de presentaci贸n: Aviso Form 144 para Ionis Pharmaceuticals, Inc. (IONS).
Venta propuesta: 10,000 acciones de Common Stock a trav茅s de Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) el 08/06/2025, con un valor de mercado agregado de $419,292.00. La presentaci贸n indica 159,391,229 acciones en circulaci贸n.
Detalles de la adquisici贸n: 42,223 acciones adquiridas como Restricted Stock Units el 01/15/2017; pago: efectivo. La presentaci贸n muestra "Nothing to Report" respecto a valores vendidos en los 煤ltimos 3 meses. Los campos de identidad del declarante/CIK y de contacto para la presentaci贸n no aparecen en el contenido del formulario.
鞝滌稖 鞙犿槙: Ionis Pharmaceuticals, Inc. (IONS)鞐� 雽�頃� Form 144 韱奠.
鞝滌晥霅� 毵る弰: 10,000欤� 氤错喌欤茧ゼ Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO)毳� 韱淀暣 08/06/2025鞐� 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜 臧�旃� $419,292.00鞛呺媹雼�. 鞝滌稖靹滌棎電� 159,391,229欤缄皜 氚滍枆霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
旆摑 雮挫棴: 42,223欤茧姅 01/15/2017鞐� Restricted Stock Units鞙茧 旆摑霅橃棃鞙茧┌; 歆�攵�: 順勱笀. 鞝滌稖靹滌棎電� 歆�雮� 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� "Nothing to Report"搿� 響滉赴霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚� 鞁犾洂/CIK 氚� 鞝滌稖 鞐半澖觳� 頃鞚� 鞏戩嫕 雮挫毄鞐� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Type de d茅p么t : Avis Form 144 pour Ionis Pharmaceuticals, Inc. (IONS).
Vente propos茅e : 10,000 actions ordinaires via Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) le 08/06/2025, pour une valeur marchande globale de $419,292.00. La d茅claration indique 159,391,229 actions en circulation.
D茅tails de l'acquisition : 42,223 actions acquises sous forme de Restricted Stock Units le 01/15/2017 ; paiement : esp猫ces. La d茅claration affiche "Nothing to Report" pour les titres vendus au cours des 3 derniers mois. Les champs relatifs 脿 l'identit茅 du d茅clarant/CIK et au contact de soumission ne figurent pas dans le contenu du formulaire.
Art der Einreichung: Form 144-Mitteilung f眉r Ionis Pharmaceuticals, Inc. (IONS).
Vorgeschlagener Verkauf: 10,000 Aktien der Common Stock 眉ber Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) am 08/06/2025, mit einem gesamten Marktwert von $419,292.00. Die Meldung weist 159,391,229 ausstehende Aktien aus.
Erwerbsdetails: 42,223 Aktien wurden am 01/15/2017 als Restricted Stock Units erworben; Zahlung: Bar. Die Meldung vermerkt "Nothing to Report" f眉r in den letzten 3 Monaten ver盲u脽erte Wertpapiere. Angaben zur Identit盲t des Meldenden/CIK und zu Einreichungskontakten sind im Formularinhalt nicht vorhanden.
- None.
- None.
Insights
TL;DR: Routine Form 144 disclosing a proposed sale of 10,000 Ionis shares on 08/06/2025; key identity details are missing from the filing.
The notice documents a proposed sale of 10,000 common shares via Stifel Nicolaus on 08/06/2025 with an aggregate market value of $419,292.00. Acquisition records show these shares originated as Restricted Stock Units on 01/15/2017 (42,223 units acquired) and were paid for in cash. The filing does not include the filer name, CIK, or submission contact details, which limits ability to assess insider status or intent. No sales in the prior three months are reported.
TL;DR: Disclosure meets Rule 144 mechanics but omits filer identification; materiality to shareholders is not determinable from this filing alone.
The Form 144 specifies the broker (Stifel Nicolaus & Company Inc), class (Common Stock), proposed sale date (08/06/2025) and aggregate value ($419,292.00). It documents the acquisition as RSUs dated 01/15/2017. Crucial identifying information (filer name/CIK) is absent from the provided content, preventing assessment of officer/director/affiliate status or compliance context beyond the mechanics disclosed.
Tipo di deposito: Avviso Form 144 per Ionis Pharmaceuticals, Inc. (IONS).
Vendita proposta: 10,000 azioni di Common Stock tramite Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) il 08/06/2025, con un valore di mercato aggregato di $419,292.00. La segnalazione indica 159,391,229 azioni in circolazione.
Dettagli sull'acquisizione: 42,223 azioni acquisite come Restricted Stock Units il 01/15/2017; pagamento: contanti. La segnalazione riporta "Nothing to Report" per titoli venduti negli ultimi 3 mesi. I campi relativi all'identit脿 del dichiarante/CIK e al contatto per l'invio non sono forniti nel contenuto del modulo.
Tipo de presentaci贸n: Aviso Form 144 para Ionis Pharmaceuticals, Inc. (IONS).
Venta propuesta: 10,000 acciones de Common Stock a trav茅s de Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) el 08/06/2025, con un valor de mercado agregado de $419,292.00. La presentaci贸n indica 159,391,229 acciones en circulaci贸n.
Detalles de la adquisici贸n: 42,223 acciones adquiridas como Restricted Stock Units el 01/15/2017; pago: efectivo. La presentaci贸n muestra "Nothing to Report" respecto a valores vendidos en los 煤ltimos 3 meses. Los campos de identidad del declarante/CIK y de contacto para la presentaci贸n no aparecen en el contenido del formulario.
鞝滌稖 鞙犿槙: Ionis Pharmaceuticals, Inc. (IONS)鞐� 雽�頃� Form 144 韱奠.
鞝滌晥霅� 毵る弰: 10,000欤� 氤错喌欤茧ゼ Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO)毳� 韱淀暣 08/06/2025鞐� 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜 臧�旃� $419,292.00鞛呺媹雼�. 鞝滌稖靹滌棎電� 159,391,229欤缄皜 氚滍枆霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
旆摑 雮挫棴: 42,223欤茧姅 01/15/2017鞐� Restricted Stock Units鞙茧 旆摑霅橃棃鞙茧┌; 歆�攵�: 順勱笀. 鞝滌稖靹滌棎電� 歆�雮� 3臧滌洈 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� "Nothing to Report"搿� 響滉赴霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚� 鞁犾洂/CIK 氚� 鞝滌稖 鞐半澖觳� 頃鞚� 鞏戩嫕 雮挫毄鞐� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Type de d茅p么t : Avis Form 144 pour Ionis Pharmaceuticals, Inc. (IONS).
Vente propos茅e : 10,000 actions ordinaires via Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) le 08/06/2025, pour une valeur marchande globale de $419,292.00. La d茅claration indique 159,391,229 actions en circulation.
D茅tails de l'acquisition : 42,223 actions acquises sous forme de Restricted Stock Units le 01/15/2017 ; paiement : esp猫ces. La d茅claration affiche "Nothing to Report" pour les titres vendus au cours des 3 derniers mois. Les champs relatifs 脿 l'identit茅 du d茅clarant/CIK et au contact de soumission ne figurent pas dans le contenu du formulaire.
Art der Einreichung: Form 144-Mitteilung f眉r Ionis Pharmaceuticals, Inc. (IONS).
Vorgeschlagener Verkauf: 10,000 Aktien der Common Stock 眉ber Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) am 08/06/2025, mit einem gesamten Marktwert von $419,292.00. Die Meldung weist 159,391,229 ausstehende Aktien aus.
Erwerbsdetails: 42,223 Aktien wurden am 01/15/2017 als Restricted Stock Units erworben; Zahlung: Bar. Die Meldung vermerkt "Nothing to Report" f眉r in den letzten 3 Monaten ver盲u脽erte Wertpapiere. Angaben zur Identit盲t des Meldenden/CIK und zu Einreichungskontakten sind im Formularinhalt nicht vorhanden.
FAQ
What does the Ionis (IONS) Form 144 report?
Who is the executing broker named in the filing?
When and how were the securities originally acquired?
Does the filing report any sales in the past three months?
Is the identity of the filer or filer CIK included in the content?
